Cellestetix, a biotechnology company focused on discovering, developing and commercializing plant-based exosome formulas for regenerative beauty care applications. Pragma Capital Partners (“PCP”), APY Ventures, Arya Ventures, Maxis Ventures, İstCapital, Ahmet Ramiz and other angel investors, and received an investment of 2 million dollars.
The investment tour will accelerate Cellestetix’s growth in the US market and contribute to new product development efforts.
Cellestetix is a team of two female genetic engineers who worked as researchers at Harvard Medical School and MD Anderson. Polen Koçak and Dr. Founded by Merve Yıldırım. The founders have over 10 years of experience in biotechnology, genetics, bioengineering and gene therapy. The company initially launched as an R&D platform for cancer and wound care. However, with the addition of former Estee Lauder executives to the management team, its focus shifted and it now focuses on cosmetic applications of plant-based exosomes under the SickScience brand in the US market.
Cellestetix offers solutions in skin renewal and beauty care with plant-based exosome formulas developed under the SickScience Labs brand. SickScience products, which entered the US market at the beginning of 2024, were featured in prestigious media outlets such as WWD, People Magazine, The Today Show and Forbes.
Cellestheticix is a subsidiary of SickScience Labs, Inc. in the USA. It aims to position itself as an independent brand under its umbrella. While exosome and product R&D studies are carried out in laboratories in Turkey, final product production and marketing are carried out in facilities in the USA.
Source link: https://webrazzi.com/2024/08/16/yerli-biyoteknoloji-sirketi-cellestetix-2-milyon-dolar-yatirim-aldi/